References
- Gale R. P., Foon K. A. Biology of chronic lym-phocytic leukemia. Sem. Hematol. 1987; 4: 209
- Hansen M. M. Chronic lymphocytic leukemia. Clinical studies based on 189 cases followed for a long time. Scand. J. Haematol. 1973; 18: 71
- Foon K. A., Rai K. R., Gale R. P. Chronic lymphocytic leukemia: New insight into biology and therapy. Ann. Intern. Med. 1990; 113: 525
- Lewis F. B., Schwartz R. S., Damashek W. X-radiation and alkylating agents as possible “trigger” mechanism in the autoimmune complications of malignant lym-phoproliferative diseases. Clin. Exper. Immunol. 1966; 1: 3
- Catovsky D., Foa R. B-cell chronic lymphocytic leukemia. The Lymphoid Leukaemias. Butterworth & Co. Ltd., London 1990; 73–112
- Thompson-Moya L., Martin T., Heuft H. G., Neubauer A., Herrmann R. Case report: Allergic reaction with immune hemolytic anemia resulting from chlorambucil. Am. J. Hematol. 1989; 32: 230
- French Cooperative Group on Chronic Lyrnphocytic Leukemia. Long term results of the CHOP regimen in stage C chronic lymphocytic leukemia. Br. J. Haematol. 1989; 73: 334
- Keating M. J. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia. Semin. Oncol. 1990; 17: 49
- Boldt D. H., Von Hoff D. D., Kuhn J. G., Hersh M. Effect on human peripheral lymphocytes of in vivo administration of 9–B-D-arabinofuranosyl-2–fluoroadenine-5'-monophosphate (NSC 312887). a new purine antimetabolite. Cancer Res. 1984; 44: 4661
- Robertson L., Huh Y., Hirsch-Ginsberg C., Kantajian H., O'Brien S., Koller C., McCredie K., Keating M. J. Clinical, immunophenotypic, and molecular analysis of the completeness of response in chronic lymphocytic leukemia after fludarabine. Blood 1990; 76: 314a, (#1245) (abstr)
- Gale R. P. A review of disordered immunity and hy-pogamma-globulinemia in chronic lymphocytic leukemia. Chronic Lymphocytic Leukemia: Recent Progress and Future Direction, R. P. Gale, K. R. Rai. Alan R. Liss, New York, NY 1987; 411
- Cheson B. D., Bennett J. M., Rai K. R., Grever M. R., Kay N. E., Schiffer C. A., Oken M. M., Keating M. J., Boldt D. H., Kempin S. J., Foon K. A. Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored working group. Am. J. Hematol. 1988; 29: 152
- Hamblin T. J., Oscier D. G., Young B. J. Au-toimmunity in chronic lymphocytic leukemia. J. Clin. Pa-thol. 1986; 39: 713
- De Rossi G., Granati L., Girelli G., Gandolfo G., Arista M. C., Martelli M., Conti L., Marini R., La Tagliata R., Leone R., Mandelli F. Incidence and prognostic significance of autoantibodies against erythrocytes and platelets in chronic lymphocytic leukemia (CLL). Nouv. Rev. Fr. Hematol. 1988; 30: 403
- Borche L., Lim A., Binet J. L., Dighiero G. Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural antibodies. Blood 1990; 76: 562
- Dighiero G. An attempt to explain disordered immunity and hypogammaglobulinemia in B-CLL. Nouv. Rev. Fr. Hematol. 1988; 30: 283
- Dighiero G., Hart S., Lim A., Miller R. A., Borche L., Levy R. Evidence that B-cell malignancies frequently involve autoreactive B-cells. Blood 1990; 76: 346a, (#1376) (abstr)